Followers | 130 |
Posts | 14996 |
Boards Moderated | 0 |
Alias Born | 06/04/2018 |
Thursday, July 04, 2019 12:10:21 PM
BARCELONA, Spain , July 4, 2019 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify ® , its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (F...
Read the whole news Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
Recent GRFS News
- Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution • GlobeNewswire Inc. • 10/29/2024 12:00:00 PM
- Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury • GlobeNewswire Inc. • 10/22/2024 12:00:00 PM
- GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat • GlobeNewswire Inc. • 10/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/25/2024 09:15:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 09:10:48 PM
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Schwab and Snowflake Retreat in Premarket, WeRide Postpones IPO, Halliburton Cyberattack, McDonald’s Instagram Hack • IH Market News • 08/22/2024 09:37:42 AM
- GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2024 06:00:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2024 03:12:47 PM
- Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News • IH Market News • 07/03/2024 10:59:39 AM
- Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years • GlobeNewswire Inc. • 07/01/2024 10:00:44 AM
- Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group • GlobeNewswire Inc. • 06/18/2024 11:30:08 AM
- Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies • GlobeNewswire Inc. • 06/17/2024 08:20:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/14/2024 09:00:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 02:51:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 08:46:16 PM
- Grifols 2023 Annual Report on Form 20-F filed with the SEC • PR Newswire (US) • 04/19/2024 08:42:00 PM
- Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. • GlobeNewswire Inc. • 04/18/2024 01:30:00 PM
- Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News • IH Market News • 04/15/2024 11:06:48 AM
- Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening • GlobeNewswire Inc. • 04/04/2024 08:00:00 AM
- FedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest News • IH Market News • 03/22/2024 01:07:53 PM
- CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News • IH Market News • 03/08/2024 11:19:59 AM
- Grifols announces positive topline phase 3 fibrinogen clinical trial results • GlobeNewswire Inc. • 02/14/2024 08:16:43 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM